EVOLVE Short DAPT – 3 Month Dual Antiplatelet Therapy (DAPT) with SYNERGYTM Stent System
Study Type/Phase: Interventional
Status: Not Recruiting
This is a prospective, multicenter study designed to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System (Synergy Stent System).
Coronary artery disease is a narrowing of one or more blood vessels (coronary arteries) that supply blood and oxygen to the heart. Coronary stenting is a commonly used procedure to treat coronary artery disease. A stent is a small mesh tube that is placed in the artery through a catheter or PCI to treat weak or narrowed arteries. The FDA approved SYNERGY stent is a drug-eluding stent that has been shown to promote healing and prevent re-narrowing of the coronary arteries. The purpose of this study will be to research the safety of aspirin plus 3 months of a second blood thinner (antiplatelet) medication [clopidogrel (Plavix), or prasugrel (Effient), or ticagrelor (Brilinta)] in people who have a SYNERGY stent.
Speak with your doctor to determine whether you meet the following criteria for participation in this study.
|Inclusion Criteria||Exclusion Criteria|
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.